Amyris and Immunitybio Complete Joint Venture For Next Generation COVID-19 Rna Vaccine
Amyris, Inc, a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, and ImmunityBio , a clinical-stage immunotherapy company, announced the completion of a previously announced joint venture agreement to accelerate the commercialization of a leading next-generation COVID-19 vaccine. Latest Fintech Insights: FTFT Subsidiary Launches......